⚖️ He emphasizes a need for proper risk assessment, enabling better production methods that could serve more patients. Closed processing systems could advance personalized medicine.
📉 However, regulatory concerns slow adoption, urging firms to innovate rather than cling to outdated methods.
Introduction:
The article discusses the need for advanced therapy manufacturers to undertake calculated regulatory risks in order to optimize the manufacturing processes for advanced therapies. David Estapé, a seasoned technology manager, emphasizes that the healthcare industry must find a balance between adhering to regulatory requirements and advancing patient care through improved manufacturing practices.
- Advanced therapy developers should balance the risks and benefits of closed system technologies, which have the potential to enhance patient care.
- Companies tend to overestimate minor risks, neglecting the benefits that innovations can bring to patient treatment.
- Estapé argues that regulatory concerns often lead companies to retain outdated technologies, thereby impacting their ability to efficiently serve patients.
- Closed processing systems can help standardize and scale manufacturing, leading to the potential treatment of thousands of patients compared to the current limits.
- The slow adoption of these technologies is attributed to overly detailed and prescriptive regulatory definitions, rather than intrinsic issues with the technologies themselves.
Conclusion:
The article concludes that for advanced therapy manufacturers to effectively address patient needs and leverage the future of biomanufacturing, they must integrate a risk-aware approach to regulatory practices. This will require a paradigm shift in understanding the probability of risks versus the potential benefits of innovative manufacturing solutions.
